Research study Program year 2025 Source: CMS Open Payments

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarl

Research payments

$2,483,935

1,009 payments

Through program year 2025, $2,483,935 in research payments was reported against A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarl, across 1,009 payments, paid by GlaxoSmithKline, LLC..

Paid by: GlaxoSmithKline, LLC.
ClinicalTrials.gov: No trial number was reported for this study

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$244,143	157
2024	Research	$482,985	295
2023	Research	$756,227	268
2022	Research	$681,965	175
2021	Research	$318,614	114

Breakdown

Who paid Research payments · program years 2021–2025

GlaxoSmithKline, LLC. $2,483,935 1,009 payments

Who received the money Research payments · program years 2021–2025

Bioclinica INC Organisation paid for research $341,190 65 payments
NYU School of Medicine Organisation paid for research $322,483 117 payments
Compassionate Care Research Group INC Organisation paid for research $197,149 119 payments
Institute For Clinical Research INC Organisation paid for research $188,260 39 payments
St Elizabeth Healthcare Organisation paid for research $115,498 75 payments
Hematology Oncology Associates Of Fredericksburg Organisation paid for research $104,708 84 payments
Univ Of Texas MD Anderson Cancer Center Organisation paid for research $98,989 38 payments
Biomedical Research Alliance Organisation paid for research $96,989 47 payments
University Of Pittsburgh Organisation paid for research $77,796 19 payments
Biomedical Research Alliance Of New York LLC Organisation paid for research $60,271 52 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

7 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.